Back to top

Press Releases

Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

CVX GSK AFL NVO MGM

Trades from $3

For Immediate Release

Chicago, IL – November 10, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Chevron (NYSE:(CVX - Free Report) – Free Report), Glaxo (NYSE:(GSK - Free Report) – Free Report), Aflac (NYSE:(AFL - Free Report) –Free Report),Novo Nordisk (NYSE:(NVO - Free Report) –Free Report) and MGM Resorts (NYSE:(MGM - Free Report) – Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for Today

Today's Research Daily features new research reports on 16 major stocks, including Chevron (NYSE:(CVX - Free Report) –Free Report), Glaxo (NYSE:(GSK - Free Report) –Free Report) and Aflac (NYSE:(AFL - Free Report) – Free Report).

Chevron ’s shares have gained more than 19% year-to-date. The analyst emphasizes that the company’s current oil and gas development project pipeline is among the best in the industry, boasting large, multi-year projects. Also, Chevron has been able to boost returns and remain competitive by embarking on aggressive cost reduction initiatives, exiting unprofitable markets and streamlining the organization.

Owing to these positives, the company has been able to report better-than-expected earnings in the third quarter. However, due to commodity price rout, Chevron’s upstream division has been able to extract less value for their products. (You canread the full research report on Chevron here .)

Glaxo ’s shares have struggled recently. Glaxo’s third-quarter 2016 results were impressive with the company beating estimates on all fronts. The analyst likes Glaxo’s diversified base and presence in different geographical areas as well as its efforts to develop its pipeline.

The performance of new products as well as those acquired from Novartis is also encouraging. These should help support revenues and ease the impact of the loss of Advair sales. However, challenges remain in the form of increasing competition, genericization and pricing pressure, which will continue to impact the company’s performance. (You can read the full research report on Glaxo here.)

Aflac ’s shares have increased by more than 8% year-to-date. Aflac’s third quarter earnings exceeded expectations and grew year over year. The analyst likes the way in which company is trying to differentiate itself from its rivals by paying claims in one day through a program named “One Day Pay.” Aflac’s strong capital position enables it to buy back shares and increase dividend payouts at regular intervals.

Efforts to increase agent productivity also will drive long-term growth. However, Aflac’s top line remains exposed to a challenging operating environment, primarily in Japan. (You can read the full research report on Aflac here.)

Other noteworthy reports we are featuring today include Novo Nordisk (NYSE:(NVO - Free Report) –Free Report) and MGM Resorts (NYSE:(MGM - Free Report) – Free Report).

Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on CVX - FREE

Get the full Report on GSK - FREE

Get the full Report on AFL - FREE

Get the full Report on NVO - FREE

Get the full Report on MGM - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.